New radioactive drug targets prostate cancer in early trial

NCT ID NCT06641219

Completed Disease control Sponsor: Tomsk National Research Medical Center of the Russian Academy of Sciences Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This small, completed Phase 1 study tested a single injection of a radioactive drug called Lutetium-177 BQ7876 in 7 men with prostate cancer. The main goals were to see how the drug spreads in the body, how much radiation reaches tumors, and whether it is safe. Because it is very early research, the results will only show if the drug behaves as expected, not if it can treat the cancer.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Lutetium-177 labeled BQ7876 (a radioactive drug)
What this could lead to: If successful, this could lead to a new targeted radiation therapy for prostate cancer that delivers radiation directly to cancer cells.
What could go wrong: This is a very early Phase 1 study with only 7 participants, so it is too small to prove effectiveness. The drug may not work as hoped or could cause unexpected side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PROSTATE CANCERS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PROSTATE CANCERS

Contacts and locations

Locations

TomskNRMC

Tomsk, 634050, Russia

More trials for these conditions

Other studies related to the condition(s) this trial covers.